The development of immune checkpoint inhibitors (ICIs) has been a major breakthrough in cancer immunotherapy. The increasing use of ICIs has led to the discovery of a broad spectrum of immune-related
The dataset includes most citations considered for inclusion in the scoping review. The citations are accessible in the Endnote file, as well as the primary citation export files from each database. T
With the extensive clinical application of immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) associated with these agents have increasingly garnered significant attention. Unl
JAAD online-only supplemental figures for "De novo cutaneous connective tissue disease associated with immune checkpoint inhibitor therapy: a retrospective analysis"
A 69-year-old female with recurrent stage IV squamous cell lung carcinoma and metastatic abdominal lymph node but not bone metastases was being treated with pembrolizumab. Four months after starting t
